SUPT6H

Across TCGA pan-cancer cohorts, SUPT6H Mutation is linked to patient survival in 14 of 34 cancer types, making it a survival-associated SUPT6H data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher SUPT6H Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SUPT6H expression acts as an unfavorable survival marker, although some lineages such as BLCA and STAD show a favorable association.

UCS, SCLC, and LUAD are the cancer types where SUPT6H Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.104	0.688	<.001	36	view →
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	18	view →
LUSC	DFS	Median	II,III,IV	0.239	0.714	<.001	17	view →
BLCA	OS	Median	II,III,IV	0.927	0.598	.022	11	view →
ACC	DFS	Median	All	0.089	0.666	.010	9	view →
PCPG	DFS	Median	All	0.229	0.822	.024	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	6	view →
STAD	OS	Median	All	1.000	0.352	.030	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.018	3	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

SUPT6H–UCS (OS)

Open the UCS breakdown →